Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
A$ 0.04
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Respiri Limited, an e-health SaaS company, researches, develops, and commercializes medical devices in Australia. The company develops, produces, and sells mobile health applications. Its products include wheezo, an electronic wheeze detection tool to detect wheeze in children; respiri mobile application; and Respiri health portal. The company was formerly known as iSonea Limited and changed its name to Respiri Limited in December 2015. Respiri Limited is based in Melbourne, Australia.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Data is available to registered users only
Buy
Sell